Shots:
- The EC has approved Novartis‘ Itvisma (onasemnogene abeparvovec) for the treatment of pts (≥2yrs.) living with 5q spinal muscular atrophy (SMA) harboring a confirmed bi-allelic mutation in the SMN1 gene
- Approval was based on the P-III (STEER) trial & supportive P-IIIb (STRENGTH) & P-I/II (STRONG) studies, where STEER showed a 2.39-point improvement in the HFMSE with effects sustained over 52wks. vs 0.51 in Sham. Both STEER & STRENGTH demonstrated benefit in treatment-naïve as well as experienced pts
- Itvisma is a gene replacement therapy that delivers a functional SMN1 gene via a single intrathecal dose, enabling sustained SMN protein expression to improve motor function in SMA pts
Ref: Novartis | Image: Novartis | Press Release
Related News: Antares Therapeutics Inks ~$1.9B Deal with Novartis for Undruggable Oncology Targets
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
